Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Crizotinib Encapsulated Microsphere vs Formulated Capsule in Healthy Adults
NCT04856293Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of crizotinib in non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Zero to Infinity, Maximum Plasma Concentration and 1 more. Started Apr 2021; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)anaplastic large cell lymphoma (ALCL)inflammatory myofibroblastic tumor (IMT)
Beyond the preview
Go deeper on NCT04856293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856293.